Ovarian Cancer

Latest News

Hospital exterior | Image Credit: Spiroview Inc. - stock.adobe.com
Greater NACT Use at High-Volume Centers Linked to Lower Surgical Mortality, Longer Survival in Advanced Ovarian Cancer

August 13th 2025

High-volume cancer centers utilizing neoadjuvant chemotherapy (NACT) significantly reduce surgical mortality and enhance survival rates in patients with advanced ovarian cancer.

Ovarian cancer awareness | Image Credit: SewcreamStudio - stock.adobe.com
Patients With Ovarian Cancer, Higher Social Vulnerability Face Delayed Treatment but Earlier Palliative Care Consultations

August 6th 2025

Ovarian cancer awareness | Image Credit: Queenmoonlite Studio - stock.adobe.com
Underuse of Maintenance Therapies Highlights Need for Improved Care Strategies in Advanced Ovarian Cancer

July 21st 2025

3D ovarian cancer illustration | Image Credit: Lars Neumann - stock.adobe.com
Updated OVARIO Trial Results Reinforce Niraparib Plus Bevacizumab Maintenance for Advanced Ovarian Cancer

July 13th 2025

GLP-1 receptor agonists | Image Credit: K KStock - stock.adobe.com
GLP-1 Receptor Agonists Show Promise as Adjunctive Treatment for Ovarian Cancer

July 11th 2025

Advancing Ovarian Cancer Treatment: Insights From Emerging Therapies

Discover how advancements in BRCA, folate receptor alpha, HER2, and CCNE1 testing are shaping ovarian cancer care while addressing barriers in education, access, and tumor diversity.

AJMC Insights logo displayed over a dark blue abstract background with flowing wave-like patterns.
Continuing Medical Education
View All
August 21st 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 21st 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

ovarian cancer
August 2nd 2023

Niraparib Maintenance Therapy Improves PFS by 55% in Advanced Ovarian Cancer

Hayden E. Klein
Results of the phase 3 PRIME study showed that treatment with niraparib with an individualized starting dose significantly extended progression-free survival (PFS) and reduced the risk of disease progression or death by 55% compared with placebo.
Doctor or psychiatrist consulting and diagnostic examining stressful woman patient on obstetric - gynecological female illness, or mental health in medical clinic or hospital healthcare service center: © Chinnapong - stock.adobe.com
July 30th 2023

Case Study Details Rare Instance of Ovarian SCC Resulting From Endometriosis

Gianna Melillo
Currently, there is no established standard of care treatment for ovarian squamous cell carcinoma (SCC).
Checkup uterus reproductive system , women's health, PCOS, ovary cancer treatment and examine, Healthy feminine concept: © Kiattisak - stock.adobe.com
July 27th 2023

Review Outlines Barriers to Guideline-Adherent Ovarian Cancer Care

Gianna Melillo
Racial minority patients and low socioeconomic status patients tended to face the most barriers.
Ovarian cancer
July 22nd 2023

Tumor Differences Associated With Survival Outcomes in HGSC Ovarian Cancer

Jared Kaltwasser
Investigators looked at both primary and metastatic tumors and found correlations between characteristics and patient outcomes.
Female Reproductive System Anatomy: © mi_viri - stock.adobe.com
July 19th 2023

In Ovarian Cancer, Postchemotherapy Immunological Modification Points to Later Relapse

Jared Kaltwasser
Most cases of high-grade serous ovarian cancer are not diagnosed until the disease has reached an advanced stage.
Chemotherapy
July 15th 2023

NACT Use Is Growing in Rare Ovarian Cancers, but Certain Patients May Not Benefit

Jaime Rosenberg
The findings come amidst growing use of the treatment approach.
OVARIAN CANCER CONCEPT: © onephoto - stock.adobe.com
July 13th 2023

Survey Details Concerns, Priorities of Women With Ovarian Cancer

Gianna Melillo
In addition to a fear of cancer recurrence, patients said feeling isolated was also a challenge associated with having ovarian cancer.
Ovarian cancer, 3D illustration: © Dr_Microbe - stock.adobe.com
July 7th 2023

Nurse Navigators Improve Rate, Timeliness of NGS in Ovarian Cancer

Jared Kaltwasser
Rates of next-generation sequencing (NGS) more than doubled once a nurse navigation program was implemented.
ovarian cancer circled | blueringmedia - stock.adobe.com
July 3rd 2023

Current Treatments, Future Strategies for Platinum-Resistant Ovarian Cancer: Review

Gianna Melillo
Outcomes for patients with this form of the disease are poor and treatment options are limited.
Kathleen Moore, MD, MS
June 30th 2023

Kathleen N. Moore, MD, MS, on Groundbreaking Result in MIRASOL: “This Is What Patients Want”

Interview by Mary Caffrey
This interview with the lead investigator of the MIRASOL trial, which was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, will appear with coverage of ASCO in the upcoming issue of Evidence-Based Oncology.
data points overlaid on icons of people
June 26th 2023

Barriers, Facilitators of Breast, Ovarian Screening Tool Implementation in Community-Based Organizations

Gianna Melillo
Latina women at risk of hereditary breast and ovarian cancer are less likely to be referred for genetic counseling and testing.
Ovarian cancer text with medications | tashatuvango - stock.adobe.com
June 23rd 2023

FDA Pauses Upifitamab Rilsodotin Trials in Platinum-Sensitive Ovarian Cancer

Russ Conroy
Following safety reports of bleeding events after treatment with upifitamab rilsodotin among patients with platinum-sensitive ovarian cancer, the FDA places a partial clinical hold on enrollment for the UP-NEXT and UPGRADE-A trials.
MIRASOL: Mirvetuximab Soravtansine Improves PFS, OS in Certain Women With Recurrent Ovarian Cancer
June 4th 2023

MIRASOL: Mirvetuximab Soravtansine Improves PFS, OS in Certain Women With Recurrent Ovarian Cancer

Mary Caffrey
The confirmatory trial showed limited side effects relative to physician's choice of chemotherapy.
ELAHERE logo
April 26th 2023

SORAYA Data Shed Light on Responses to Mirvetuximab Soravtansine Based on Prior Bevacizumab Exposure

AJMC Staff
The antibody drug conjugate received FDA approval in November 2022.
Neil Iyengar, MD
February 21st 2023

Neil Iyengar, MD, Emphasizes Importance of Population Health Lens in Oncology

Hayden E. Klein
FDA Approves Mirvetuximab Soravtansine-gynx for Platinum-Resistant Ovarian Cancer
November 15th 2022

FDA Approves Mirvetuximab Soravtansine-gynx for Platinum-Resistant Ovarian Cancer

Laura Joszt, MA
In addition to the drug approval, the FDA approved a companion diagnostic to be used to identify patients who are eligible to receive the treatment.
Ovarian cancer graphic
February 15th 2021

Proximity to Treatment, Racial Disparities Are Seen in Ovarian Cancer Survival

Maggie L. Shaw
Patients with ovarian cancer who lived within 10 miles of Kansas’s only National Cancer Institute–designated cancer center, and those of a non-White race, were shown to have less of a survival advantage.
Whitney Goldsberry, MD, University of Alabama at Birmingham
February 12th 2021

Dr Whitney Goldsberry on the Future of PARP Inhibitors in Ovarian Cancer

Whitney Goldsberry, MD, clinician at the University of Alabama at Birmingham Hospital and fellow at the UAB Division of Gynecologic Oncology, gives her insight into the future of PARP inhibitors in ovarian cancer treatment.
Doctor-patient consult
February 11th 2021

Choice of Ovarian Cancer Surgery Influenced by Risk Perception

Maggie L. Shaw
An investigation of 24 women from the United Kingdom’s PROTECTOR trial has revealed that their concerns toward cancer risk and menopause affect their choice of surgery as treatment for ovarian cancer.
Dr Whitney Goldsberry on Cost-Sharing Trends in PARP Inhibitors for Ovarian Cancer
February 6th 2021

Dr Whitney Goldsberry on Cost-Sharing Trends in PARP Inhibitors for Ovarian Cancer

Whitney Goldsberry, MD, fellow at the University of Alabama's Division of Gynecologic Oncology, discusses findings from her and colleagues' recent analysis of cost-sharing trends for PARP inhibitors in ovarian cancer treatment.
Laparoscopy Shown to Be Cost-effective in Evaluating Newly Diagnosed Ovarian Cancer
February 5th 2021

Laparoscopy Shown to Be Cost-effective in Evaluating Newly Diagnosed Ovarian Cancer

AJMC Staff
Researchers from MD Anderson Cancer Center found that laparoscopy cost more upfront but eliminated wasteful treatment decisions.
Recent Adavosertib Results in Ovarian Cancer Could Be Sign of Things to Come
January 30th 2021

Recent Adavosertib Results in Ovarian Cancer Could Be Sign of Things to Come

Mary Caffrey
Recent results with adavosertib in ovarian cancer could signal future positive results, given the number of trials using the targeted therapy with the PARP inhibitor olaparib.
Site Logo
January 20th 2021

Lauren M. Corduck, Founder of Oneinforty, Dies at 49; Advocated for Change in BRCA Testing Guidelines

Mary Caffrey
Lauren M. Corduck, who turned a diagnosis of ovarian cancer into a crusade to educate others with similar genetic mutations, died on December 24, 2020. She was 49.
Older Patient Consulting With Doctor
January 15th 2021

Aggressive Treatment Might Benefit Older Patients With Ovarian Cancer

Rose McNulty
Certain elderly women with ovarian cancer might benefit from aggressive treatment methods, a study recently published in Annals of Surgical Oncology found.
Jessica Greenwood, MS
January 15th 2021

Payer Coverage Is the Key to Cost-effective Panel Testing in Gynecological Cancers

Mary Caffrey
Panel testing for genetic variants linked to more cancers is cost-effective than just testing or BRCA1/2 mutations, says a clinical director for a women's health company.
Daniel F. Hayes, MD
January 9th 2021

What Is Clinical Utility in a Tumor Biomarker Test? Former ASCO President Knows It When He Sees It

Mary Caffrey
Daniel F. Hayes, MD, offers definitions and an algorithm for clinicians to define clinical utility.
women pain
January 9th 2021

Study Finds Link Between Larger Endometriomas and Ovarian Cancer

AJMC Staff
A study links the size of cysts associated with endometriosis with coexistent ovarian cancer.
Dr Bradley Monk Discusses Indications for PARP Inhibitors in Ovarian Cancer
December 30th 2020

Dr Bradley Monk Discusses Indications for PARP Inhibitors in Ovarian Cancer

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, describes the current indications for PARP inhibitors in ovarian cancer.
Bradley Monk, MD
December 28th 2020

Dr Bradley Monk on Response to PARP Inhibitors in Ovarian Cancer

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, discusses the ovarian cancer patients most likely to respond well to PARP inhibition.
Bradley Monk, MD
December 26th 2020

Dr Bradley Monk on the Changing Regulatory Landscape of PARP Inhibitors

Rose McNulty
Bradley Monk, MD, FACOG, FACS, a professor at the University of Arizona, chronicles the regulatory changes in PARP inhibitors as they gain more indications in ovarian cancer.
<1234567>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo